



Press Release

Friday, October 30, 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Financial Performance Q3-2009

Revenue up by 17% EBITDA up by 134%

**Revenue from Operations at Rs. 3,171 Million up by 17%, and
EBITDA at Rs.426 Million up by 134%**

Source: Limited Review of Company Consolidated Financials, IGAAP

Strides Arcolab Limited today announced results of its limited review of financials for the third quarter ended September 30, 2009.

Highlights for the quarter

Consolidated results

- Revenue from operations at Rs. 3,171 Million in Q3'09 against Rs. 2,721 Million in Q3 '08.
- EBITDA for Q3'09 at Rs. 426 Million as against Rs. 182 Million in Q3'08
- PAT after excluding exceptional Forex gains & Divestment gains at Rs. 124 Million in Q3'09 as compared to loss of Rs. 24 Million in Q3'08.

Stand Alone results

- Revenue from operations at Rs. 1,657 Million in Q3'09 against Rs. 1,663 Million in Q3'08.
- PAT at Rs. 42 Million in Q3'09 as compared to a loss of Rs. 517 Million in Q3'08.

Other Highlights

Launch of Starflu:

- Launch of Starflu (Oseltamivir) for the treatment of Influenza – A (H1N1) Commenced supplies to Ministry of Health, Government of India

Reorganisation:

- The Hon'ble High Court of Judicature at Bombay sanctioned the Composite Scheme of Arrangement between Grandix Pharmaceuticals Limited, Grandix Laboratories Limited, Global Remedies Limited and Quantum Remedies Private Limited ('Transferor Companies') with Strides Arcolab Limited (Transferee Company). The approvals from Hon'ble High Courts of Karnataka and Chennai are awaited.

Regulatory approvals:

- USFDA Approval for two more products one each for Steriles and Orals. Total approval for Steriles at 17 and Orals at 13.

Ascent tie up with Pfizer

- Ascent entered into an agreement with Pfizer to sell and promote Pfizer off-patent products in Australia

Commenting on Q3 09 results, Strides Arcolab's Vice Chairman & Group CEO Mr. Arun Kumar stated "I am happy that we have been delivering continued growth Quarter-after-Quarter. The Key business drivers have performed in line with our internal targets and we look forward to another year of superior performance".

Qtr-on Qtr (Consolidated) Highlights		Figures in INR Millions	
Particulars	Q-3'09	Q-3'08	Growth
Operational Revenue	3,171	2,721	17%
Total Revenue	3,191	2,763	
EBITDA	426	182	134%
PBT before exceptional items	98	(41)	100+%

YTD 9 months (Consolidated) Highlights		Figures in INR Millions	
Particulars	Sept'09	Sept'08	Growth
Operational Revenue	9,112	7,345	24%
Total Revenue	9,218	7,794	
EBITDA	1,268	1,136	12%
PBT before exceptional items	349	394	

Note: Previous period numbers have been recast / restated wherever necessary to conform to the current period classification.

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company's website at www.stridesarco.com

For further information, please contact

Mr. T.S. Rangan, Group CFO Tel: +91 80 6658 0115	Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 9880376648 Email: maheshn@corvoshandwick.co.in
Mr.N.Kannan, Company Secretary Tel : +91 80 6658 0751	Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: +91 9916728393 Email: kasturi@corvoshandwick.co.in